Sitagliptin: a potential drug for the treatment of COVID-19? Cover

.blurhash-client-img { display: none !important; }

Sitagliptin: a potential drug for the treatment of COVID-19?

Acta Pharmaceutica

Volume 71 (2021): Issue 2 (June 2021)

By: Sanaa K. Bardaweel, Rima Hajjo and Dima A. Sabbah

Open Access

|Nov 2020

Authors

Sanaa K. Bardaweel

S.Bardaweel@ju.edu.jo

Department of Pharmaceutical Sciences School of Pharmacy, University of Jordan, Amman, Jordan

Rima Hajjo

Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Jordan

Dima A. Sabbah

Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Jordan

DOI: https://doi.org/10.2478/acph-2021-0013 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075

Journal RSS Feed

Language: English

Page range: 175 - 184

Accepted on: Apr 15, 2020

|

Published on: Nov 4, 2020

Published by: Croatian Pharmaceutical Society

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

drug repurposing,

Related subjects:

Pharmacy, other

© 2020 Sanaa K. Bardaweel, Rima Hajjo, Dima A. Sabbah, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 71 (2021): Issue 2 (June 2021)Next article